Allan Coukell is Pew’s senior director for health programs. He oversees initiatives related to drug and medical device innovation and safety, medical conflicts-of-interest, the pharmaceutical supply chain, pharmacy compounding, antibiotic resistance, prescription drug abuse, FDA and specialty drugs, food safety, school nutrition, as well as other efforts related to health costs and care delivery.
Prior to joining Pew, he practiced as a clinical pharmacist in oncology at the London Health Sciences Center and Ontario Regional Cancer Center, served as a senior medical writer and editor with the medical journal publisher Adis International, and covered health and science as a reporter and producer for WBUR (NPR) in Boston and Radio New Zealand. He is Vice Chair of the Medical Device Innovation Consortium and a board member of the Reagan Udall Foundation for the FDA. He served previously as consumer representative on the FDA’s Cardiovascular and Renal Drugs Advisory Committee.
In a political climate in which the two major parties don’t always see eye to eye, one issue is bringing them together. Republicans and Democrats agree that we must address the tragedy of prescription drug abuse. With 44 people dying every day from overdoses of oxycodone, hydrocodone, and similar opioid pain relievers, recognition is growing that misuse of these drugs is a complex disease... Read More
On Feb. 1, The Pew Charitable Trusts submitted a letter to Michael Botticelli, director of the White House Office of National Drug Control Policy, offering recommendations to strengthen the 2016 National Drug Control Strategy. Read More
On Jan. 21, The Pew Charitable Trusts sent a letter to Senators Lamar Alexander (R-TN) and Patty Murray (D-WA) expressing support for the National All Schedules Prescription Electronic Reporting Reauthorization Act of 2015. Read More